|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TSPYL2 |
Gene summary for TSPYL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TSPYL2 | Gene ID | 64061 |
| Gene name | TSPY like 2 | |
| Gene Alias | CDA1 | |
| Cytomap | Xp11.22 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | Q9H2G4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64061 | TSPYL2 | GSM4909277 | Human | Breast | Precancer | 3.67e-05 | 7.34e-01 | 0.0177 |
| 64061 | TSPYL2 | GSM4909280 | Human | Breast | Precancer | 1.08e-04 | 5.93e-01 | 0.0305 |
| 64061 | TSPYL2 | GSM4909296 | Human | Breast | IDC | 5.10e-04 | -1.73e-01 | 0.1524 |
| 64061 | TSPYL2 | GSM4909311 | Human | Breast | IDC | 1.91e-05 | -1.94e-01 | 0.1534 |
| 64061 | TSPYL2 | GSM4909312 | Human | Breast | IDC | 7.95e-05 | -2.03e-01 | 0.1552 |
| 64061 | TSPYL2 | GSM4909319 | Human | Breast | IDC | 1.24e-08 | -1.19e-01 | 0.1563 |
| 64061 | TSPYL2 | NCCBC14 | Human | Breast | DCIS | 1.81e-05 | -2.19e-01 | 0.2021 |
| 64061 | TSPYL2 | NCCBC5 | Human | Breast | DCIS | 1.04e-02 | -2.00e-01 | 0.2046 |
| 64061 | TSPYL2 | P1 | Human | Breast | IDC | 1.86e-04 | -1.14e-01 | 0.1527 |
| 64061 | TSPYL2 | DCIS2 | Human | Breast | DCIS | 1.51e-40 | 1.66e-01 | 0.0085 |
| 64061 | TSPYL2 | LZE4T | Human | Esophagus | ESCC | 1.08e-07 | 4.50e-01 | 0.0811 |
| 64061 | TSPYL2 | LZE7T | Human | Esophagus | ESCC | 2.30e-05 | 4.33e-01 | 0.0667 |
| 64061 | TSPYL2 | LZE24T | Human | Esophagus | ESCC | 2.73e-23 | 7.75e-01 | 0.0596 |
| 64061 | TSPYL2 | LZE21T | Human | Esophagus | ESCC | 2.09e-05 | 5.86e-01 | 0.0655 |
| 64061 | TSPYL2 | LZE6T | Human | Esophagus | ESCC | 4.88e-03 | 2.52e-01 | 0.0845 |
| 64061 | TSPYL2 | P1T-E | Human | Esophagus | ESCC | 1.46e-08 | 7.37e-01 | 0.0875 |
| 64061 | TSPYL2 | P2T-E | Human | Esophagus | ESCC | 6.55e-28 | 6.20e-01 | 0.1177 |
| 64061 | TSPYL2 | P4T-E | Human | Esophagus | ESCC | 1.96e-35 | 9.32e-01 | 0.1323 |
| 64061 | TSPYL2 | P5T-E | Human | Esophagus | ESCC | 1.74e-11 | 2.89e-01 | 0.1327 |
| 64061 | TSPYL2 | P8T-E | Human | Esophagus | ESCC | 3.96e-10 | 1.54e-01 | 0.0889 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000633811 | Prostate | Tumor | chromatin remodeling | 63/3246 | 255/18723 | 1.73e-03 | 1.02e-02 | 63 |
| GO:0016049112 | Thyroid | PTC | cell growth | 225/5968 | 482/18723 | 4.75e-12 | 2.07e-10 | 225 |
| GO:0001558111 | Thyroid | PTC | regulation of cell growth | 188/5968 | 414/18723 | 4.13e-09 | 1.09e-07 | 188 |
| GO:000632520 | Thyroid | PTC | chromatin organization | 183/5968 | 409/18723 | 2.55e-08 | 5.70e-07 | 183 |
| GO:00457867 | Thyroid | PTC | negative regulation of cell cycle | 166/5968 | 385/18723 | 1.93e-06 | 2.64e-05 | 166 |
| GO:00062606 | Thyroid | PTC | DNA replication | 114/5968 | 260/18723 | 3.09e-05 | 2.95e-04 | 114 |
| GO:004592614 | Thyroid | PTC | negative regulation of growth | 105/5968 | 249/18723 | 3.76e-04 | 2.54e-03 | 105 |
| GO:00063385 | Thyroid | PTC | chromatin remodeling | 106/5968 | 255/18723 | 6.56e-04 | 4.13e-03 | 106 |
| GO:00303087 | Thyroid | PTC | negative regulation of cell growth | 80/5968 | 188/18723 | 1.28e-03 | 7.31e-03 | 80 |
| GO:001604927 | Thyroid | ATC | cell growth | 241/6293 | 482/18723 | 4.27e-14 | 2.35e-12 | 241 |
| GO:000155826 | Thyroid | ATC | regulation of cell growth | 201/6293 | 414/18723 | 1.57e-10 | 4.76e-09 | 201 |
| GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
| GO:0006325110 | Thyroid | ATC | chromatin organization | 189/6293 | 409/18723 | 6.40e-08 | 1.13e-06 | 189 |
| GO:000626013 | Thyroid | ATC | DNA replication | 124/6293 | 260/18723 | 1.58e-06 | 1.93e-05 | 124 |
| GO:004592622 | Thyroid | ATC | negative regulation of growth | 115/6293 | 249/18723 | 2.34e-05 | 2.06e-04 | 115 |
| GO:003030813 | Thyroid | ATC | negative regulation of cell growth | 90/6293 | 188/18723 | 3.35e-05 | 2.78e-04 | 90 |
| GO:000633813 | Thyroid | ATC | chromatin remodeling | 109/6293 | 255/18723 | 1.38e-03 | 7.15e-03 | 109 |
| GO:00718242 | Thyroid | ATC | protein-DNA complex subunit organization | 103/6293 | 241/18723 | 1.84e-03 | 9.03e-03 | 103 |
| GO:00062756 | Thyroid | ATC | regulation of DNA replication | 50/6293 | 107/18723 | 3.25e-03 | 1.46e-02 | 50 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TSPYL2 | SNV | Missense_Mutation | rs782709479 | c.1036C>T | p.Arg346Trp | p.R346W | Q9H2G4 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
| TSPYL2 | SNV | Missense_Mutation | c.1933N>A | p.Glu645Lys | p.E645K | Q9H2G4 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.956) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TSPYL2 | SNV | Missense_Mutation | novel | c.1993N>T | p.Gly665Trp | p.G665W | Q9H2G4 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.717) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TSPYL2 | SNV | Missense_Mutation | c.963N>C | p.Met321Ile | p.M321I | Q9H2G4 | protein_coding | tolerated(0.11) | possibly_damaging(0.869) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TSPYL2 | SNV | Missense_Mutation | c.923N>C | p.Met308Thr | p.M308T | Q9H2G4 | protein_coding | deleterious(0) | possibly_damaging(0.751) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| TSPYL2 | SNV | Missense_Mutation | novel | c.1714G>A | p.Glu572Lys | p.E572K | Q9H2G4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.956) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TSPYL2 | SNV | Missense_Mutation | novel | c.1792N>A | p.Asp598Asn | p.D598N | Q9H2G4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.977) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TSPYL2 | SNV | Missense_Mutation | novel | c.1699G>A | p.Glu567Lys | p.E567K | Q9H2G4 | protein_coding | deleterious_low_confidence(0) | benign(0.135) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
| TSPYL2 | SNV | Missense_Mutation | rs782211234 | c.1369G>A | p.Glu457Lys | p.E457K | Q9H2G4 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.899) | TCGA-EW-A6SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tch | SD |
| TSPYL2 | insertion | Frame_Shift_Ins | novel | c.1379_1380insCACTGGGTGGGATATAACTGTATTTATATGC | p.Tyr461ThrfsTer16 | p.Y461Tfs*16 | Q9H2G4 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 64061 | TSPYL2 | NA | BROMODEOXYURIDINE | 11395479 | ||
| 64061 | TSPYL2 | NA | RETINOIC ACID | 15823505 | ||
| 64061 | TSPYL2 | NA | TGFBETA1 | 15823505 | ||
| 64061 | TSPYL2 | NA | SODIUM BUTYRATE | 12619135 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |